A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder
A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder
Background: Binge-eating disorder (BED) is associated with impaired quality of life and has a number of untoward public health associations. There are few established pharmacological treatments for BED, and available options are not suitable for all individuals. Vortioxetine is a recently developed pharmacological agent with effects on the serotonergic but also other neurochemical systems, which has yet to be evaluated in this context. Method: Eighty adults with BED were recruited for a double-blind, placebo-controlled study. Participants received 12-week treatment with vortioxetine (10 mg/day for 1 week, then increasing to 20 mg/day) or placebo in a parallel design. The primary efficacy outcome measures were binge-eating frequency and weight. Safety data were collected. Effects of active versus placebo treatment were characterized using linear repeated measures models. Results: Both vortioxetine and placebo treatment were associated with significant reductions in binge-eating frequency. Vortioxetine did not differentiate significantly from placebo on any efficacy measure. Frequency of adverse events did not differ between groups. Discussion: Vortioxetine was not more effective than placebo in the treatment of BED. The ability to detect pharmacological treatment benefit may have been hindered by the relatively high placebo response and drop out. Future work should seek to better understand and predict placebo response in BED, with a view to more targeted treatment interventions and, potentially, sample enrichment.
antidepressant, binge eating, obesity, pharmacology, treatment
786-794
Grant, Jon E.
07372bd5-8a0d-42b4-b41b-e376c652acf3
Valle, Stephanie
fdb6f4ca-a7e1-4e3d-bbf5-4dd380570aa5
Cavic, Elizabeth
0811dc24-44e4-4758-b4db-e83d39bc5a79
Redden, Sarah A.
f2109178-7158-46c7-971f-4a602a3adf59
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
July 2019
Grant, Jon E.
07372bd5-8a0d-42b4-b41b-e376c652acf3
Valle, Stephanie
fdb6f4ca-a7e1-4e3d-bbf5-4dd380570aa5
Cavic, Elizabeth
0811dc24-44e4-4758-b4db-e83d39bc5a79
Redden, Sarah A.
f2109178-7158-46c7-971f-4a602a3adf59
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Grant, Jon E., Valle, Stephanie, Cavic, Elizabeth, Redden, Sarah A. and Chamberlain, Samuel R.
(2019)
A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder.
International Journal of Eating Disorders, 52 (7), .
(doi:10.1002/eat.23078).
Abstract
Background: Binge-eating disorder (BED) is associated with impaired quality of life and has a number of untoward public health associations. There are few established pharmacological treatments for BED, and available options are not suitable for all individuals. Vortioxetine is a recently developed pharmacological agent with effects on the serotonergic but also other neurochemical systems, which has yet to be evaluated in this context. Method: Eighty adults with BED were recruited for a double-blind, placebo-controlled study. Participants received 12-week treatment with vortioxetine (10 mg/day for 1 week, then increasing to 20 mg/day) or placebo in a parallel design. The primary efficacy outcome measures were binge-eating frequency and weight. Safety data were collected. Effects of active versus placebo treatment were characterized using linear repeated measures models. Results: Both vortioxetine and placebo treatment were associated with significant reductions in binge-eating frequency. Vortioxetine did not differentiate significantly from placebo on any efficacy measure. Frequency of adverse events did not differ between groups. Discussion: Vortioxetine was not more effective than placebo in the treatment of BED. The ability to detect pharmacological treatment benefit may have been hindered by the relatively high placebo response and drop out. Future work should seek to better understand and predict placebo response in BED, with a view to more targeted treatment interventions and, potentially, sample enrichment.
This record has no associated files available for download.
More information
Published date: July 2019
Keywords:
antidepressant, binge eating, obesity, pharmacology, treatment
Identifiers
Local EPrints ID: 493323
URI: http://eprints.soton.ac.uk/id/eprint/493323
ISSN: 0276-3478
PURE UUID: 247f7063-1b98-46ce-9199-0b201053d417
Catalogue record
Date deposited: 29 Aug 2024 16:49
Last modified: 30 Aug 2024 02:00
Export record
Altmetrics
Contributors
Author:
Jon E. Grant
Author:
Stephanie Valle
Author:
Elizabeth Cavic
Author:
Sarah A. Redden
Author:
Samuel R. Chamberlain
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics